It, 6/15, is in fact lower than 50%, however the 50% question...

It, 6/15, is in fact lower than 50%, however the 50% question was wrt the first part of Sheba II, where the response rate was 3 out of 6, which is, you may recognise, 50%.

With regard to "is this any good?" There's a concise ASX announcement from today that mentions that a response rate of 40% overall in a population with this level of pre-treatment is outstanding. "For example, an efficacious AML treatment that might work in 70% of patients as a first line therapy may only work in 5% of patients who receive it as a fifth-line therapy."

Thank you for the Dorothy Dixer, aereola90, it is any good; an independent specialist called it "impressive"; the author of the abstract called it "rather impressive". If it doesn't seem impressive to you it would seem that this is because you're no expert.

There's the added little tidbit that there was no cardio toxicity observed when the combination drugs are known to be cardio toxic - the Triangle report estimated very conservatively that a cardio protective anti cancer synergy drug could be worth tens of billions of dollars. This result suggests that this dream is alive and well; bisantrene could be benefiting literally millions of people in the future.